This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now

AbbVie posted Q2 revenue up 10.2% YoY to nearly $17B and adjusted EPS up 23% YoY to $3.65, supported by Skyrizi and Rinvoq momentum. Management expects Skyrizi and Rinvoq to total $31B in sales this year and says neither loses patent exclusivity until the next decade. The company also announced a $10.9B acquisition of Apogee Therapeutics, adding immunology assets (zumilokibart) to replace future growth pillars, while maintaining its 54-year streak of dividend increases.

Analysis

ABBV is still being priced like a post-Humira repair story, but the more important mechanism is concentration risk versus visibility. If the immunology franchise keeps compounding above consensus, the market can justify a higher multiple because the cash stream starts resembling a durable annuity rather than a single-product rollover; if not, the stock reverts to a low-growth pharma valuation fast. Near term, the key is not the dividend narrative but whether management can keep reinvesting free cash flow into assets that extend the franchise without destroying returns.

The Apogee move is strategically sensible, but it is better viewed as an insurance premium on future growth than a near-term EPS driver. Second-order, this raises the bar for smaller immunology and dermatology developers: ABBV can now either buy or outlast them, which should compress takeout speculation in the sub-sector while supporting a higher M&A floor for differentiated assets. The flip side is that paying up for late-stage immunology before clear differentiation is proven can become a signal of scarcity rather than conviction.

The consensus may be underestimating how much of ABBV’s upside depends on just a few read-throughs and reimbursement trends over the next 1-3 quarters. The thesis is falsified if immunology growth decelerates, if launch economics for the replacement pipeline disappoint, or if integration/financing of bolt-ons starts to crowd out buybacks and dividend growth. Over 6-18 months, the stock can work as a defensive compounder, but the market will likely demand proof that the next growth leg is broader than the current two-drug core.

Key Decisions for Investors

• Long ABBV on 1-3% pullbacks; target a 10-15% total return over 6-12 months if immunology growth stays above consensus and the multiple expands by 1-2 turns.
• Pair trade: long ABBV / short XBI for a 3-6 month horizon; the trade favors cash-generative durability over biotech beta and should work if risk appetite fades or clinical data remain mixed.
• Do not chase APGE after takeover optimism; treat it as a binary pipeline option. Only add on clinical validation or if the spread widens enough to offer asymmetric upside relative to deal break risk.
• Watch ABBV guidance and same-franchise growth in the next two earnings cycles; if management is forced to rely on acquisitions to sustain top-line growth, reduce exposure.
• If you want income exposure, prefer ABBV over higher-yield but lower-visibility pharma peers; the downside case is slower multiple expansion, not dividend stress.